Pharmaceutical Chemistry

Drug Discovery and Therapy

Submit Abstract Register Now

National Cancer Institute (NCI) provides preclinical cancer research, which includes evaluating the preclinical safety and pharmacokinetics of chemotherapeutics and chemopreventive agents. Many research Laboratories also provides genetic toxicology testing for NCI's chemoprevention program, synthesizes compounds for NCI's carcinogen repository, and manufactures clinical trial materials.

National Cancer Institute (NCI) funded for Tumour Glycome Laboratories. They are the principal component of the trans-NIH Alliance of Glycobiologists for Detection of Cancer and Cancer Risk, which is searching for glycan-based biomarkers for breast, ovarian, lung, prostate and pancreatic cancers and melanoma.

More than 30 years of research has led to numerous drugs on the market or ready for licensing, including:

·         Targretin® (bexarotene), a retinoid receptor ligand marketed by Eisai

·         Tirapazamine, a hypoxic tissue-selective cytotoxin

·         TAS-108, a selective estrogen receptor modulator licensed to Taiho Pharmaceutical

·         PDX (pralatrexate), an antimetabolite licensed to Allos Therapeutics

·         SR16157, a dual estrone sulfatase / ER antagonist for breast cancer treatment